Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain | Clinical Pharmacy and Pharmacology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
The National Prescribing Centre. Pain Overview—Data Focused Commentaries. http://www.npc.nhs.uk/therapeutics/pain/overview/data.php. Updated April 2010. Accessed September 22, 2014.
2.
Manchikanti  L, Helm  S  II, Fellows  B,  et al.  Opioid epidemic in the United States.  Pain Physician. 2012;15(3)(suppl):ES9-ES38.PubMedGoogle Scholar
3.
Grandvuillemin  A, Jolimoy  G, Authier  F, Dautriche  A, Duhoux  F, Sgro  C.  Tramadol-induced hypoglycemia: 2 cases [in French].  Presse Med. 2006;35(12, pt 1):1842-1844.PubMedGoogle ScholarCrossref
4.
Tavassoli  N, Lapeyre-Mestre  M, Sommet  A, Montastruc  J-L; French Association of Regional Pharmacovigilance Centres.  Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol).  Br J Clin Pharmacol. 2009;68(3):422-426.PubMedGoogle ScholarCrossref
5.
Taugourdeau  S, Chiche  L, Rouby  F,  et al.  Severe hypoglycemia induced by tramadol: two new cases of an unlisted side effect [in French].  Rev Med Interne. 2011;32(11):703-705.PubMedGoogle ScholarCrossref
6.
Jonville-Bera  A-P, Marie  A, Magba  D, Gedon  E, Autret-Leca  E.  Tramadol-induced hypoglycemia in a diabetic patient [in French].  Therapie. 2010;65(5):499-500.PubMedGoogle ScholarCrossref
7.
Mugunthan  N, Davoren  P.  Danger of hypoglycemia due to acute tramadol poisoning.  Endocr Pract. 2012;18(6):e151-e152.PubMedGoogle ScholarCrossref
8.
Bourne  C, Gouraud  A, Daveluy  A,  et al; French Association of Regional Pharmacovigilance Centres.  Tramadol and hypoglycaemia: comparison with other step 2 analgesic drugs.  Br J Clin Pharmacol. 2013;75(4):1063-1067.PubMedGoogle ScholarCrossref
9.
Bonds  DE, Miller  ME, Bergenstal  RM,  et al.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.  BMJ. 2010;340:b4909.PubMedGoogle ScholarCrossref
10.
Zoungas  S, Patel  A, Chalmers  J,  et al; ADVANCE Collaborative Group.  Severe hypoglycemia and risks of vascular events and death.  N Engl J Med. 2010;363(15):1410-1418.PubMedGoogle ScholarCrossref
11.
McCoy  RG, Van Houten  HK, Ziegenfuss  JY, Shah  ND, Wermers  RA, Smith  SA.  Increased mortality of patients with diabetes reporting severe hypoglycemia.  Diabetes Care. 2012;35(9):1897-1901.PubMedGoogle ScholarCrossref
12.
Cryer  PE.  Death during intensive glycemic therapy of diabetes: mechanisms and implications.  Am J Med. 2011;124(11):993-996.PubMedGoogle ScholarCrossref
13.
Raffa  RB, Friderichs  E, Reimann  W, Shank  RP, Codd  EE, Vaught  JL.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic.  J Pharmacol Exp Ther. 1992;260(1):275-285.PubMedGoogle Scholar
14.
García Rodríguez  LA, Pérez Gutthann  S.  Use of the UK General Practice Research Database for pharmacoepidemiology.  Br J Clin Pharmacol. 1998;45(5):419-425.PubMedGoogle ScholarCrossref
15.
Herrett  E, Thomas  SL, Schoonen  WM, Smeeth  L, Hall  AJ.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review.  Br J Clin Pharmacol. 2010;69(1):4-14.PubMedGoogle ScholarCrossref
16.
Khan  NF, Harrison  SE, Rose  PW.  Validity of diagnostic coding within the General Practice Research Database: a systematic review.  Br J Gen Pract. 2010;60(572):e128-e136.PubMedGoogle ScholarCrossref
17.
Suissa  S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom  BL, ed.  Pharmacoepidemiology.4th ed. Chichester, England: John Wiley & Sons, Ltd; 2006:811-829.
18.
Miettinen  OS, Caro  JJ.  Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions.  J Clin Epidemiol. 1989;42(4):325-331.PubMedGoogle ScholarCrossref
19.
Schneeweiss  S, Rassen  JA, Glynn  RJ, Avorn  J, Mogun  H, Brookhart  MA.  High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.  Epidemiology. 2009;20(4):512-522.PubMedGoogle ScholarCrossref
20.
Maclure  M.  The case-crossover design: a method for studying transient effects on the risk of acute events.  Am J Epidemiol. 1991;133(2):144-153.PubMedGoogle Scholar
21.
Hebert  C, Delaney  JAC, Hemmelgarn  B, Lévesque  LE, Suissa  S.  Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs.  Pharmacoepidemiol Drug Saf. 2007;16(8):845-849.PubMedGoogle ScholarCrossref
22.
Suissa  S.  The case-time-control design.  Epidemiology. 1995;6(3):248-253.PubMedGoogle ScholarCrossref
23.
Cepeda  MS, Camargo  F, Zea  C, Valencia  L.  Tramadol for osteoarthritis: a systematic review and metaanalysis.  J Rheumatol. 2007;34(3):543-555.PubMedGoogle Scholar
24.
Chaparro  LE, Furlan  AD, Deshpande  A, Mailis-Gagnon  A, Atlas  S, Turk  DC.  Opioids compared to placebo or other treatments for chronic low-back pain.  Cochrane Database Syst Rev. 2013;8:CD004959.PubMedGoogle Scholar
25.
Donovan  MH, Tecott  LH.  Serotonin and the regulation of mammalian energy balance.  Front Neurosci. 2013;7:36.PubMedGoogle ScholarCrossref
26.
Yamada  J, Sugimoto  Y, Kimura  I, Takeuchi  N, Horisaka  K.  Serotonin-induced hypoglycemia and increased serum insulin levels in mice.  Life Sci. 1989;45(20):1931-1936.PubMedGoogle ScholarCrossref
27.
Chi  T-C, Ho  Y-J, Chen  W-P,  et al.  Serotonin enhances beta-endorphin secretion to lower plasma glucose in streptozotocin-induced diabetic rats.  Life Sci. 2007;80(20):1832-1838.PubMedGoogle ScholarCrossref
28.
Derijks  HJ, Meyboom  RHB, Heerdink  ER,  et al.  The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports.  Eur J Clin Pharmacol. 2008;64(5):531-538.PubMedGoogle ScholarCrossref
29.
Derijks  HJ, Heerdink  ER, De Koning  FH, Janknegt  R, Klungel  OH, Egberts  AC.  The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study.  Pharmacoepidemiol Drug Saf. 2008;17(4):336-344.PubMedGoogle ScholarCrossref
30.
Cheng  JT, Liu  IM, Chi  TC, Tzeng  TF, Lu  FH, Chang  CJ.  Plasma glucose-lowering effect of tramadol in streptozotocin-induced diabetic rats.  Diabetes. 2001;50(12):2815-2821.PubMedGoogle ScholarCrossref
31.
Ray  WA.  Evaluating medication effects outside of clinical trials: new-user designs.  Am J Epidemiol. 2003;158(9):915-920.PubMedGoogle ScholarCrossref
32.
Khalid  JM, Raluy-Callado  M, Curtis  BH, Boye  KS, Maguire  A, Reaney  M.  Rates and risk of hospitalisation among patients with type 2 diabetes: retrospective cohort study using the UK General Practice Research Database linked to English Hospital Episode Statistics.  Int J Clin Pract. 2014;68(1):40-48.PubMedGoogle ScholarCrossref
Original Investigation
February 2015

Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain

Author Affiliations
  • 1Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
  • 2Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
  • 3Department of Oncology, McGill University, Montreal, Quebec, Canada
  • 4Laboratoire de Pharmacologie Médicale et Clinique, Equipe de Phamacoepidémiologie Institut National de la Santé et de la Recherche Médicale U1027, Faculté de Médecine, Université Paul Sabatier, Toulouse, France
  • 5Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
JAMA Intern Med. 2015;175(2):186-193. doi:10.1001/jamainternmed.2014.6512
Abstract

Importance  Tramadol is a weak opioid analgesic whose use has increased rapidly, and it has been associated with adverse events of hypoglycemia.

Objective  To assess whether tramadol use, when compared with codeine use, is associated with an increased risk of hospitalization for hypoglycemia.

Design, Setting, and Participants  A nested case-control analysis was conducted within the United Kingdom Clinical Practice Research Datalink linked to the Hospital Episodes Statistics database of all patients newly treated with tramadol or codeine for noncancer pain between 1998 and 2012. Cohort and case-crossover analyses were also conducted to assess consistency of the results.

Main Outcomes and Measures  Cases of hospitalization for hypoglycemia were matched with up to 10 controls on age, sex, and duration of follow-up. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated comparing use of tramadol with codeine. A cohort analysis, with high-dimensional propensity score–adjusted hazard ratios (HRs) and 95% CIs, was performed comparing tramadol with codeine in the first 30 days after treatment initiation. Finally, a case-crossover analysis was also performed, in which exposure to tramadol in a 30-day risk period immediately before the hospitalization for hypoglycemia was compared with 11 consecutive 30-day control periods. Odds ratios and 95% CIs were estimated using conditional logistic regression analysis.

Results  The cohort included 334 034 patients, of whom 1105 were hospitalized for hypoglycemia during follow-up (incidence, 0.7 per 1000 per year) and matched to 11 019 controls. Compared with codeine, tramadol use was associated with an increased risk of hospitalization for hypoglycemia (OR, 1.52 [95% CI, 1.09-2.10]), particularly elevated in the first 30 days of use (OR, 2.61 [95% CI, 1.61-4.23]). This 30-day increased risk was confirmed in the cohort (HR, 3.60 [95% CI, 1.56-8.34]) and case-crossover analyses (OR, 3.80 [95% CI, 2.64-5.47]).

Conclusions and Relevance  The initiation of tramadol therapy is associated with an increased risk of hypoglycemia requiring hospitalization. Additional studies are needed to confirm this rare but potentially fatal adverse event.

×